Bristol-Myers Squibb (BMY) 10-K Summary — Year Ended Dec 31, 2024
The company reported a net loss for the year despite higher revenue. Operating cash flow remained positive, and management believes it has sufficient liquidity to meet near-term obligations.
Key takeaway
Year ended Dec 31, 2024 · FY2025 10-K
The company reported a net loss for the year despite higher revenue. Operating cash flow remained positive, and management believes it has sufficient liquidity to meet near-term obligations.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$48.3B
Revenue reported for the fiscal year.
Operating income
n/a
Income from operations reported for the year.
Net income
-$8.9B
Net income reported for the year.
Operating cash flow
$15.2B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $46.4B | n/a |
| Dec 31, 2022 | $46.2B | -0.5% |
| Dec 31, 2023 | $45B | -2.5% |
| Dec 31, 2024 | $48.3B | +7.3% |
Business overview
The company's business overview covers acquisitions, product exclusivity, research and development, alliances, marketing, competition, pricing, regulation, manufacturing, and human capital management.
Financial performance
Revenue increased compared to the prior year. Net income was negative, while operating cash flow was positive.
Material risks
The filing does not provide specific risk descriptions in the supplied context. Only a reference to risk factors is included.
Liquidity and capital
The company's net debt position increased. Management expects existing cash and cash from operations to fund dividends, capital expenditures, working capital, and other needs for the next few years.
What to watch
The trend in revenue growth, as it recently turned positive after a decline.